DE60209251T2 - Adenosine a2a receptor antagonisten - Google Patents

Adenosine a2a receptor antagonisten Download PDF

Info

Publication number
DE60209251T2
DE60209251T2 DE60209251T DE60209251T DE60209251T2 DE 60209251 T2 DE60209251 T2 DE 60209251T2 DE 60209251 T DE60209251 T DE 60209251T DE 60209251 T DE60209251 T DE 60209251T DE 60209251 T2 DE60209251 T2 DE 60209251T2
Authority
DE
Germany
Prior art keywords
alkyl
alkoxy
group
mmol
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209251T
Other languages
German (de)
English (en)
Other versions
DE60209251D1 (de
Inventor
J. Julius Monmouth Junction MATASI
P. John Ringwood CALDWELL
Deen Lebanon TULSHIAN
S. Lisa Apartment No. 1 Metuchen SILVERMAN
R. Bernard West Orange NEUSTADT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60209251D1 publication Critical patent/DE60209251D1/de
Publication of DE60209251T2 publication Critical patent/DE60209251T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60209251T 2001-11-30 2002-11-26 Adenosine a2a receptor antagonisten Expired - Lifetime DE60209251T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33429301P 2001-11-30 2001-11-30
US334293P 2001-11-30
PCT/US2002/038134 WO2003048164A2 (en) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
DE60209251D1 DE60209251D1 (de) 2006-04-20
DE60209251T2 true DE60209251T2 (de) 2006-11-09

Family

ID=23306533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209251T Expired - Lifetime DE60209251T2 (de) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonisten

Country Status (18)

Country Link
US (1) US7041666B2 (enExample)
EP (1) EP1453835B1 (enExample)
JP (2) JP4284181B2 (enExample)
KR (1) KR20050044607A (enExample)
CN (1) CN1596258A (enExample)
AR (1) AR038366A1 (enExample)
AT (1) ATE317844T1 (enExample)
AU (1) AU2002346572A1 (enExample)
CA (1) CA2468681C (enExample)
DE (1) DE60209251T2 (enExample)
ES (1) ES2258164T3 (enExample)
HU (1) HUP0402270A3 (enExample)
IL (1) IL161572A0 (enExample)
MX (1) MXPA04005156A (enExample)
PE (1) PE20030739A1 (enExample)
TW (1) TW200300686A (enExample)
WO (1) WO2003048164A2 (enExample)
ZA (1) ZA200404160B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544200A1 (en) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CN101310724A (zh) 2002-12-19 2008-11-26 先灵公司 腺苷A2a受体拮抗剂的应用
US20070010522A1 (en) * 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
CA2541989C (en) * 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
AR050926A1 (es) * 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US8835631B2 (en) * 2007-05-24 2014-09-16 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
CA2690748A1 (en) * 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100093764A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093756A1 (en) * 2008-10-13 2010-04-15 Berbay J Kent HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010061696A1 (ja) 2008-11-25 2010-06-03 日産自動車株式会社 導電部材及びこれを用いた固体高分子形燃料電池
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
JP7065113B2 (ja) * 2017-04-07 2022-05-11 南京明徳新薬研発有限公司 A2A受容体阻害剤としての[1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体
CA3092470A1 (en) * 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CN112105617B (zh) * 2018-04-28 2022-04-05 南京明德新药研发有限公司 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法
JP7391046B2 (ja) * 2018-05-18 2023-12-04 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピリミジン誘導体
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピラジン誘導体
TWI820209B (zh) 2018-09-12 2023-11-01 大陸商迪哲(江蘇)醫藥股份有限公司 三唑并-嘧啶化合物及其用途
WO2020106560A1 (en) * 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12466831B2 (en) * 2018-11-20 2025-11-11 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
EA202191498A1 (ru) 2018-11-30 2021-08-20 Мерк Шарп энд Доум Корп. 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
BR112021011948A2 (pt) 2018-12-20 2021-09-08 Incyte Corporation Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
DE69428977T2 (de) 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
AU743910B2 (en) 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
CN1328560A (zh) 1998-09-22 2001-12-26 协和发酵工业株式会社 [1,2,4]三唑并[1,5-c]嘧啶衍生物
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
WO2002079204A1 (en) * 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
WO2003048163A1 (en) 2001-11-30 2003-06-12 Schering Corporation [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
EP1453835A2 (en) 2004-09-08
WO2003048164A2 (en) 2003-06-12
ES2258164T3 (es) 2006-08-16
TW200300686A (en) 2003-06-16
KR20050044607A (ko) 2005-05-12
HUP0402270A3 (en) 2008-09-29
IL161572A0 (en) 2004-09-27
CA2468681C (en) 2011-01-25
DE60209251D1 (de) 2006-04-20
CA2468681A1 (en) 2003-06-12
HK1064100A1 (en) 2005-01-21
CN1596258A (zh) 2005-03-16
MXPA04005156A (es) 2004-08-11
PE20030739A1 (es) 2003-08-28
JP2005511698A (ja) 2005-04-28
HUP0402270A2 (hu) 2005-02-28
JP4284181B2 (ja) 2009-06-24
ATE317844T1 (de) 2006-03-15
US7041666B2 (en) 2006-05-09
WO2003048164A3 (en) 2003-10-16
EP1453835B1 (en) 2006-02-15
JP2008303217A (ja) 2008-12-18
AU2002346572A1 (en) 2003-06-17
AR038366A1 (es) 2005-01-12
US20030212080A1 (en) 2003-11-13
ZA200404160B (en) 2005-04-08

Similar Documents

Publication Publication Date Title
DE60209251T2 (de) Adenosine a2a receptor antagonisten
DE60110219T2 (de) Adenosin a2a rezeptor antagonisten
DE602004008303T2 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60125335T2 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
EP1448565B1 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
DE602004010785T2 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE69724789T2 (de) Bicyclische heteroaromatic verbindungen als protein tyrosin kinase inhibitoren
DE60219196T2 (de) BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
DE60204452T2 (de) Pyrazolo[1,5a]Pyridinderivate
DE69918552T2 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen
DE60315615T2 (de) Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
DE60314623T2 (de) Substituierte pyrazolopyrimidine
DE60211343T2 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
EP0885226A1 (de) 4-amino-pyrimidin-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2004018474A1 (de) Phenyl-substituierte pyrazolopyrimidine
DE602004005960T2 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
WO2004026876A1 (de) Alkyl-substituierte pyrazolopyrimidine
DE60213629T2 (de) Piperidinverbindungen als muscarinantagonisten
DE602004007658T2 (de) Indolderivate mit verbesserter antipsychotischer wirkung
DE60220385T2 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE69007905T2 (de) 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus.
DE69926776T2 (de) Quinalozinon-derivate
DE60209014T2 (de) Tricylische CRF Rezeptorantagonisten
DE69827614T2 (de) Chinoxalindionen
DE60315311T2 (de) C-substituierte trizyklische isoxazolin derivate und deren verwendung als anti-depressiva

Legal Events

Date Code Title Description
8364 No opposition during term of opposition